ATE263572T1 - Verwendung von gastrin fragmenten oder sythetischen analogen von gastrin zur herstellung eines arzneimittels zur behandlung der helicobacter pylori assozierten störungen - Google Patents
Verwendung von gastrin fragmenten oder sythetischen analogen von gastrin zur herstellung eines arzneimittels zur behandlung der helicobacter pylori assozierten störungenInfo
- Publication number
- ATE263572T1 ATE263572T1 AT99926719T AT99926719T ATE263572T1 AT E263572 T1 ATE263572 T1 AT E263572T1 AT 99926719 T AT99926719 T AT 99926719T AT 99926719 T AT99926719 T AT 99926719T AT E263572 T1 ATE263572 T1 AT E263572T1
- Authority
- AT
- Austria
- Prior art keywords
- gastrin
- sythetical
- analogues
- helicobacter pylori
- associated disorders
- Prior art date
Links
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical group C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 title abstract 4
- 241000590002 Helicobacter pylori Species 0.000 title abstract 2
- 229940037467 helicobacter pylori Drugs 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 102100021022 Gastrin Human genes 0.000 abstract 2
- 108010052343 Gastrins Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 abstract 1
- 102000052874 Gastrin receptors Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Nanotechnology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8977098P | 1998-06-18 | 1998-06-18 | |
| US14719599P | 1999-05-20 | 1999-05-20 | |
| PCT/IL1999/000335 WO1999065513A2 (en) | 1998-06-18 | 1999-06-17 | Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE263572T1 true ATE263572T1 (de) | 2004-04-15 |
Family
ID=26780929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99926719T ATE263572T1 (de) | 1998-06-18 | 1999-06-17 | Verwendung von gastrin fragmenten oder sythetischen analogen von gastrin zur herstellung eines arzneimittels zur behandlung der helicobacter pylori assozierten störungen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6815414B2 (de) |
| EP (1) | EP1087783B1 (de) |
| JP (1) | JP2003522105A (de) |
| AT (1) | ATE263572T1 (de) |
| AU (1) | AU768612B2 (de) |
| CA (1) | CA2331834A1 (de) |
| DE (1) | DE69916273T2 (de) |
| WO (1) | WO1999065513A2 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| US20040001842A1 (en) * | 1997-05-12 | 2004-01-01 | Dov Michaeli | Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors |
| CA2328501A1 (en) * | 1998-05-15 | 1999-11-25 | Aphton Corporation | Prevention and treatment of hypergastrinemia |
| AU3003701A (en) * | 1999-11-19 | 2001-05-30 | Axxima Pharmaceuticals Ag | Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| US6849409B2 (en) | 2000-10-16 | 2005-02-01 | Axxima Pharmaceuticals Ag | Cellular kinases involved in Cytomegalovirus infection and their inhibition |
| CA2441228A1 (en) | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
| US20090191232A1 (en) | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| US20030021786A1 (en) * | 2001-07-09 | 2003-01-30 | Gevas Philip C. | Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| US6810583B2 (en) * | 2001-08-07 | 2004-11-02 | International Business Machines Corporation | Coupling of conductive vias to complex power-signal substructures |
| IL152289A0 (en) * | 2002-10-14 | 2003-05-29 | Vectabiotics Ltd | Method and composition for inhibiting h.pylori infection in a mammalian tissue |
| WO2004088326A2 (en) * | 2003-03-28 | 2004-10-14 | Aphton Corporation | Gastrin hormone immunoassays |
| DK1794586T3 (da) * | 2004-09-22 | 2013-05-13 | Cancer Advances Inc | Monoklonale antistoffer til progastrin |
| US20060121031A1 (en) * | 2004-12-07 | 2006-06-08 | Mckenzie Brent S | Relay vaccine |
| US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| PL2046334T3 (pl) | 2006-07-25 | 2015-02-27 | Vecta Ltd | Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI |
| EP2720605B1 (de) | 2011-06-14 | 2020-03-11 | Gravitas Medical Inc. | Vorrichtung zur durchführung einer medizinischen versorgung auf basis einer erkannten magenfunktion |
| US9700514B1 (en) | 2014-08-20 | 2017-07-11 | Darren Rubin | Single solid oral dosage forms for treating Helicobacter pylori infection and duodenal ulcer disease |
| EP3624841A4 (de) | 2017-06-15 | 2021-01-27 | Cancer Advances, Inc., | Zusammensetzungen und verfahren zur induzierung humoraler und zellulärer immunitäten gegen tumore und krebs |
| US12150978B2 (en) | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
| US11263510B2 (en) * | 2020-07-15 | 2022-03-01 | GM Global Technology Operations LLC | Method for performing measurements of dendritic structures for all magnifications and camera resolutions of microscopes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1204430B (it) * | 1986-01-10 | 1989-03-01 | Alfio Bertolini | Composizioni farmaceutiche comprendenti peptidi del gruppo colecistochinina-cerulina per il trattamento terapeutico degli stati di shock e dell'insufficienza respiratoria e cardiocircolatoria |
| DK0380230T3 (da) * | 1989-01-24 | 1995-01-16 | Aphton Corp | Immunogene sammensætninger mod gastrin-peptider |
| US4997950A (en) * | 1989-04-20 | 1991-03-05 | Richard Finbar Murphy | Novel C-terminal gastrin antagonists |
| JP3718890B2 (ja) * | 1995-12-28 | 2005-11-24 | 味の素株式会社 | Ｎ−ベンゾイルプロリンエステル誘導体 |
-
1999
- 1999-06-17 AU AU43882/99A patent/AU768612B2/en not_active Ceased
- 1999-06-17 AT AT99926719T patent/ATE263572T1/de not_active IP Right Cessation
- 1999-06-17 JP JP2000554391A patent/JP2003522105A/ja active Pending
- 1999-06-17 CA CA002331834A patent/CA2331834A1/en not_active Abandoned
- 1999-06-17 DE DE69916273T patent/DE69916273T2/de not_active Expired - Fee Related
- 1999-06-17 WO PCT/IL1999/000335 patent/WO1999065513A2/en not_active Ceased
- 1999-06-17 EP EP99926719A patent/EP1087783B1/de not_active Expired - Lifetime
-
2000
- 2000-12-15 US US09/738,948 patent/US6815414B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999065513A3 (en) | 2000-03-02 |
| EP1087783A2 (de) | 2001-04-04 |
| US6815414B2 (en) | 2004-11-09 |
| JP2003522105A (ja) | 2003-07-22 |
| WO1999065513A2 (en) | 1999-12-23 |
| DE69916273D1 (de) | 2004-05-13 |
| AU768612B2 (en) | 2003-12-18 |
| CA2331834A1 (en) | 1999-12-23 |
| US20010020005A1 (en) | 2001-09-06 |
| DE69916273T2 (de) | 2005-05-19 |
| AU4388299A (en) | 2000-01-05 |
| EP1087783B1 (de) | 2004-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE263572T1 (de) | Verwendung von gastrin fragmenten oder sythetischen analogen von gastrin zur herstellung eines arzneimittels zur behandlung der helicobacter pylori assozierten störungen | |
| SE9803710D0 (sv) | Use of certain drugs for treating nerve root injury | |
| UY26130A1 (es) | Compuestos para tratar la obesidad | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| BRPI0417376A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização | |
| BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| NO20083956L (no) | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| BG104727A (en) | Pharmaceutical composition of topiramate | |
| BRPI0518222A (pt) | composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos | |
| ATE506059T1 (de) | Therapie zur behandlung der überaktiven blase | |
| EA200801711A1 (ru) | Пролекарства возбуждающих аминокислот | |
| ATE431141T1 (de) | Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit | |
| ATE387912T1 (de) | Transepikutane darreichungsform zur behandlung des restless leg syndroms | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| BR0313718A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| BRPI0410654A (pt) | composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| MXPA02011921A (es) | Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona. | |
| DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| DE69733169D1 (de) | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs | |
| IT1307786B1 (it) | Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali. | |
| MY135972A (en) | Egg anti-inflammatory composition and method of treating and preventing inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |